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The activation of the innate immune system 
involves a complex interplay between protein 
phosphorylation  and  protein  ubiquitylation 
events. For example, the activation of Toll-like 
receptors (TLRs) that signal through the adap-
tor protein MyD88 switches on protein ki-
nases, such as IL-1 receptor–associated kinases 
(IRAKs), and E3 ubiquitin ligases, such as TNF 
receptor–associated factor (TRAF) 6 (Walsh   
et al., 2008) and Pellino (Ordureau et al., 2008). 
These E3 ligases are then thought to induce 
the formation of Lys63-linked polyubiquitin 
(K63-pUb) chains, which may be linked co-
valently to other proteins, such as IRAK1 and 
TRAF6 (Wang et al., 2001; Conze et al., 2008; 
Windheim et al., 2008), or may not be anchored 
to any other protein (Xia et al., 2009).
The K63-pUb chains and K63-pUb-proteins   
regulate  downstream  signaling  pathways  by 
  interacting  with  polyubiquitin-binding  pro-
teins that include the regulatory components 
of  other  protein  kinases.  For  example,  the 
binding of K63-pUb chains to the TAB2 and 
TAB3  components  of  the TAK1  complex 
(Kanayama et al., 2004; Kulathu et al., 2009; 
Sato  et  al.,  2009)  induces  a  conformational 
change that activates this protein kinase (Xia 
et al., 2009), enabling TAK1 to initiate activa-
tion of the canonical inhibitor of NF-B (IB) 
kinase  (IKK)  complex. The  NF-B  essential   
modulator (NEMO) component of the ca-
nonical IKK complex also binds to K63-pUb 
chains, and mutations that abrogate its bind-
ing to polyubiquitin (e.g., NEMO[D311N]) 
prevent  activation  of  the  IKKs  (Ea  et  al., 
2006; Wu et al., 2006) and NF-B–dependent 
gene transcription (Windheim et al., 2008) 
in response to inflammatory stimuli and cause   
immunoinsufficiency in man (Döffinger et al., 
2001). These findings imply that the binding of 
polyubiquitin to NEMO is required for activa-
tion of the canonical IKKs, as well as the activa-
tion of TAK1. The K63-pUb chains may act as 
scaffolds to colocalize the IKK complex with 
TAK1, and/or their interaction with NEMO 
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The protein ABIN1 possesses a polyubiquitin-binding domain homologous to that present in 
nuclear factor B (NF-B) essential modulator (NEMO), a component of the inhibitor of NF-B 
(IB) kinase (IKK) complex. To address the physiological significance of polyubiquitin binding, 
we generated knockin mice expressing the ABIN1[D485N] mutant instead of the wild-type 
(WT) protein. These mice developed all the hallmarks of autoimmunity, including spontaneous 
formation of germinal centers, isotype switching, and production of autoreactive antibodies. 
Autoimmunity was suppressed by crossing to MyD88/ mice, demonstrating that toll-like 
receptor (TLR)–MyD88 signaling pathways are needed for the phenotype to develop. The B cells 
and myeloid cells of the ABIN1[D485N] mice showed enhanced activation of the protein kinases 
TAK, IKK-/, c-Jun N-terminal kinases, and p38 mitogen-activated protein kinase and 
produced more IL-6 and IL-12 than WT. The mutant B cells also proliferated more rapidly in 
response to TLR ligands. Our results indicate that the interaction of ABIN1 with polyubiquitin is 
required to limit the activation of TLR–MyD88 pathways and prevent autoimmunity.
© 2011 Nanda et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it  is  available  under  a  Creative  Commons  License  (Attribution–Noncommer-
cial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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but also from binding to linear polyubiquitin chains (Rahighi 
et al., 2009). Linear polyubiquitin chains are thought to be gen-
erated by the LUBAC E3-ligase (Kirisako et al., 2006) and to 
may induce a conformational change that facilitates phos-
phorylation of the activation loop of the canonical IKKs by 
TAK1 and/or autophosphorylation.
The canonical IKKs activate NF-B by phosphorylating 
the inhibitory IB component of this transcription factor, 
which marks IB for K48-linked polyubiquitylation by the 
SCFTRCP E3 ligase and proteasomal destruction. The canonical 
IKKs also switch on the protein kinase Tpl2 by phosphorylat-
ing its inhibitory p105/NF-B1 component. Similarly, TAK1 
not only initiates activation of the canonical IKKs but is also   
required to activate c-Jun N-terminal kinase (JNK) and p38 
mitogen-activated protein kinase (MAPK) via the  TLR–MyD88 
signaling pathway. The canonical IKKs and MAPKs then cata-
lyze many further phosphorylation events that control the 
transcription, translation, processing, and secretion of inflam-
matory mediators (Sato et al., 2005; Shim et al., 2005).
Interestingly, the polyubiquitin-binding domain in NEMO, 
originally termed A20-binding inhibitor of NF-B (ABIN) 
homology domain 2 (AHD2; Heyninck et al., 2003), but later 
renamed the ubiquitin-binding domain in ABIN and NEMO 
(UBAN; Wagner et al., 2008), is found in four other human 
proteins, termed NRP (NEMO-related protein, also called op-
tineurin), ABIN1, ABIN2, and ABIN3.  The ABINs are so named 
because they were originally identified in a yeast two-hybrid 
screen using the protein deubiquitylase A20 as bait and because 
they were found to inhibit NF-B–dependent gene transcrip-
tion when overexpressed in cells (Heyninck et al., 1999).
Recently, ABIN1 knockout mice were generated and char-
acterized (Oshima et al., 2009). These mice were found at nor-
mal Mendelian ratios up to embryonic day (E) 18.5, but the 
embryos were smaller and more anemic than WT embryos and 
died during late embryogenesis from fetal liver apoptosis and 
hypoplasia. Embryonic fibroblasts isolated from the ABIN1/ 
mice were hypersensitive to TNF-induced programmed cell 
death and the lethality could be rescued by crossing to mice that 
did not express the TNFR1 receptor (Oshima et al., 2009).
To understand the physiological role of the polyubiquitin-
binding function of ABIN1, we generated knockin mice that 
express the ABIN1[D485N] mutant instead of the WT protein, 
a mutation which is equivalent to the polyubiquitin binding-
defective NEMO[D311N] mutant described already. Unex-
pectedly, these knockin mice had a quite different phenotype 
from the ABIN1/ mice. They were born at normal Mende-
lian frequencies and the adults were of normal size and weight. 
However, they then developed a lupus-like autoimmune dis-
ease, which could be prevented by crossing to MyD88-deficient 
mice. These and other results presented in this paper demon-
strate that the interaction of ABIN1 with polyubiquitin chains 
limits the strength of signaling downstream of TLR-MyD88 
and that this is critical to prevent autoimmunity.
RESULTS
Interaction of ABIN1 with polyubiquitin chains in vitro  
and generation of ABIN1[D485N] knockin mice
The mutation of Asp311 of NEMO to Asn prevents it not only 
from binding to K63-pUb chains (Ea et al., 2006; Wu et al., 2006)   
Figure 1.  Binding to Lys63-linked or linear polyubiquitin chains is 
disrupted by a point mutation in the UBAN of ABIN1 or NEMO.  
(A and B) The binding of WT and mutant human ABIN1 and NEMO to poly-
ubiquitin chains is described in Materials and methods. Polyubiquitin chains 
captured by the immobilized proteins were released by denaturation in 1% 
(wt/vol) SDS, subjected to SDS-PAGE and immunoblotted with an anti- 
ubiquitin antibody (Dako). (A) Lanes 1 and 6 show, respectively, the K48-linked 
and K63-linked polyubiquitin preparations used in the experiment. The binding 
of K48-linked (lanes 2 and 3) and K63-linked (lanes 7 and 8) polyubiquitin 
chains to WT ABIN1 (left) or NEMO (right) and to the ABIN1[D472N] and 
NEMO[D311N] mutants (lanes 4, 5, 9, and 10, left and right) is shown. Similar 
results were obtained in two different experiments. (B) As in A, except that 
binding to linear polyubiquitin oligomers was studied. Lanes 1–3 show the  
di-ubiquitin and nona-ubiquitin preparations used in the experiment. Lane 4 
shows the lack of binding to di-ubiquitin, lane 6 the binding to nona-ubiquitin, 
and lane 8 the selective capture of nona-ubiquitin by ABIN1 and NEMO when 
presented with a mixture of nona-ubiquitin and di-ubiquitin, and lanes 5, 7, 
and 9 the lack of binding of ABIN1[D472N] and NEMO[D311N] to linear  
ubiquitin oligomers. Similar results were obtained in two different experiments. 
Gray lines indicate that intervening lanes were spliced out. (C) BMDM from 
ABIN1[D485N] and WT mice were stimulated with 100 ng/ml LPS for the times 
indicated. ABIN1 was immunoprecipitated from the cell extracts and immuno-
blotted with anti-IRAK1 (top), anti-ubiquitin (middle), and anti-ABIN1 (bottom) 
antibodies. Similar results were obtained in two different experiments.JEM Vol. 208, No. 6 
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ABIN1[D485N] mutant was unable to bind to 
polyubiquitin  chains  in  vivo,  we  immunopre-
cipitated the endogenous ABIN1 from BMDM 
extracts, followed by immunoblotting with anti-
IRAK1 (to detect polyubiquitylated-IRAK1) 
and  anti-ubiquitin. These  experiments  showed 
that stimulation with LPS induced the binding of 
ABIN1 to polyubiquitylated IRAK1 (Windheim 
et al., 2008) but not to unmodified IRAK1. In 
contrast,  the  ABIN1[D485N]  mutant  did  not 
capture polyubiquitylated IRAK1 (Fig. 1 C).
Gross analysis of ABIN1[D485N] knockin mice
The ABIN1[D485N] mice were the same size and weight as 
WT littermates (Fig. 2 A) and were born at the expected 
Mendelian frequencies (not depicted). However, examination 
of their internal organs at 2–3 mo of age revealed enlarged 
spleens which, by 4 mo, were four to five times the weight of 
those from WT mice (Fig. 2 A). Both the white pulp and the 
red pulp were greatly enlarged in the spleen, although the 
splenic architecture was maintained (Fig. 2 B).
ABIN1[D485N]  knockin  mice  had  significantly  en-
larged LNs (Fig. 2 C) and 60–70% of the knockin mice had 
large nodule-like  structures  on  the  intestinal  wall,  which 
were identified as Peyer’s Patches (Fig. 2, D and E). The 
size and number of these nodules varied between animals 
and resulted from plasmocytosis and infiltration of neutro-
phils  (Fig.  2  E). Although  young ABIN1[D485N]  mice   
appeared to be superficially healthy, by 20 wk they all de-
veloped signs of severe autoimmunity, resulting in the ma-
jority of the knockin mice being terminated by 6 mo of 
age. This phenotype was exacerbated in the female mice dur-
ing pregnancy.
play an important role in activation of NF-B by TNF 
(Haas et al., 2009; Tokunaga et al., 2009). Before making a 
knockin mouse expressing a polyubiquitin-binding defective 
mutant of ABIN1, we therefore investigated whether the mu-
tation to Asn of Asp472, the residue equivalent to Asp311 of 
NEMO, also prevented binding of human ABIN1 to poly-
ubiquitin. When presented with a mixture of small ubiquitin 
oligomers linked via Lys63, ABIN1, like NEMO, preferen-
tially captured the largest polyubiquitin chains in the prepara-
tion but did not bind detectably to K48-linked ubiquitin 
oligomers under the conditions tested (Fig. 1 A). ABIN1, like 
NEMO, also captured a linear ubiquitin oligomer consisting   
of nine ubiquitins but did not capture linear di-ubiquitin in   
our assay (Fig. 1 B). The ABIN1[D472N] mutant, like the 
NEMO[D311N]  mutant,  did  not  bind  to  either  K63-
linked (Fig. 1 A) or linear (Fig. 1 B) polyubiquitin chains. 
We therefore generated a knockin mouse in which WT 
ABIN1 was replaced by the ABIN1[D485N] mutant, which 
is equivalent to the ABIN1[D472N] mutant of human ABIN1 
(Fig. S1, A and B).
The ABIN1[D485N] mutant was expressed at similar 
levels to WT ABIN1 in BM-derived macrophages (BMDMs), 
B cells, and T cells (Fig. S1, C–E). To check that the mouse 
Figure 2.  Spontaneous development of defects in 
multiple immune organs in ABIN1[D485N] mice.  
(A) Mean spleen weight (left) and body weight (middle) of 
WT and ABIN1[D485N] knockin mice with a typically en-
larged spleen in 4-mo-old mutant mice (right). Bar, 1 cm. 
(B) Representative photomicrograph of hematoxylin and 
eosin–stained spleen sections from WT and ABIN1[D485N] 
mice. The red (R) and white (W) pulp are indicated. Bars, 
0.05 mm. (C) Axillary, inguinal, and mesenteric LNs of  
5-mo-old ABIN1[D485N] mice compared with WT mice. 
Bars, 1 cm. (D) Gut-associated lymphoid tissue (arrows) of 
the small intestine wall of ABIN1[D485N] (bottom) and WT 
(top) mice. Bars, 1 cm. (E) Hematoxylin and eosin–stained 
sections of Peyer’s patches (PP) in WT and ABIN1[D485N] 
mice. In the low-power view (top; bars, 0.5 mm), the  
arrows indicate Peyer’s patches in ABIN[D485N mice com-
pared with WT mice. In the high-power view (bottom; bar, 
0.05 mm), there are Peyer’s patches showing plasma cells 
(white arrows) and neutrophils (black arrow) in the 
ABIN1[D485N] mice. All mice used were 16–20 wk old. 
Data are representative of at least 12 mice (A–C) and  
6 mice (D and E) of each genotype. Error bars show the 
mean ± SEM. **, P < 0.005 (two-tailed Students t test).1218 ABIN1 polyubiquitin binding prevents autoimmunity | Nanda et al.
the proportions of different B cell populations in the spleen, 
LNs, and peritoneal cavity of the ABIN1[D485N] mice did 
not differ significantly from those in the WT mice (Figs. S2, 
B–E). We also found that the ABIN1[D485N] knockin mice 
had four to five times the normal level of monocytes in the 
blood (unpublished data).
T cell development in the thymus was normal (Fig. S2 F). In 
contrast, analysis of the splenic and LN T cell populations dem-
onstrated an increased proportion of activated effector T cells 
(CD62Llo and CD44hi) and a reduced proportion of naive T cells 
(CD62Lhi) compared with age-matched controls (Fig. 3 D). 
Defects in immune cells with spontaneous germinal center 
formation in the ABIN1[D485N] knockin mice
To investigate immunological changes in the mice, we per-
formed flow cytometry analyses of various lymphoid organs. 
Analysis of splenic and LN cells revealed more B cells and 
granulocytes (CD11b+ Gr-1+) in the ABIN1[D485N] mice 
compared with WT mice (Fig. 3, A and B; and Fig. S2 A). The 
expression of MHCII and CD86 receptors on B cells was also 
increased in the spleen (Fig. 3 C) and LNs (not depicted) of 
the ABIN1[D485N] mice, indicating that the B cells were 
activated. However, the development of B cells in the BM and 
Figure 3.  Defects in immune cells with spontaneous germinal center formation in ABIN1[D485N] mice. (A–F and H) Flow cytometric profiles of 
spleen (SPL) and LNs. Profiles were gated on: lymphocytes by FSC/SSC (C–F and H); live cells (A); TCR-+ CD4+ (D and E), and B220+ (C and F). The numbers 
within figures indicate the percentages of different cells. GC B, germinal center B cell. (A) Flow cytometric dot plots of spleen (top) and LN (bottom) show-
ing frequencies of the CD11b+ GR-1+ (macrophages and granulocytes) population in ABIN1[D485N] and WT mice. (B) Total cell numbers in spleens of 
ABIN1[D485N] mice compared with WT. Error bars show the mean ± SEM. ***, P < 0.001 (two-tailed Students t test). (C) Expression of B cell activation 
markers from WT (shaded area) and ABIN1[D485N] (black line). (D–F) Contour plots (left) and graphical analysis (right) showing percentages of cell popu-
lations in spleen (top) and LN (bottom). Each symbol represents one mouse and the horizontal bars show the mean of the values obtained. (D) Activated 
(CD4+ CD44hi CD62Llo) and naive (CD4+ CD62Lhi) T cells. (E) Tfh cells (CD4+ CXCR5+ PD-1 hi). (F) Germinal center B cells (B220+ GL-7+ CD95+). (G) Immuno-
histochemistry of spleens from 16-wk-old mice with germinal centers (brown) stained with peanut agglutinin (PNA). Bars, 0.5 mm. (H) Expression of 
CD138 and B220 in spleen showing plasma cells in ABIN1[D485N] mice and WT mice. All mice analyzed were 12–16 wk old, and data are representative of 
at least three independent experiments with three to four mice of each genotype (A-F and H) or single experiment with six mice per genotype (G).JEM Vol. 208, No. 6 
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Elevated levels of immunoglobulins and autoantibodies  
in the serum of ABIN1[D485N] mice
The hyperplasia of Tfh cells and germinal center B cells in the 
spleen and LN led us to investigate the serum immunoglobu-
lins levels. A variety of immunoglobulin isotypes were elevated 
in the ABIN1[D485N] knockin mice compared with age-
matched WT mice, which included both T cell–dependent and 
T cell–independent immunoglobulins. In particular, the levels 
of pathogenic immunoglobulins were increased significantly 
after 20 wk (Fig. 4 A). The circulating levels of antinuclear anti-
bodies and antibodies against double-stranded (ds) DNA were 
also increased significantly after 16 wk (Fig. 4 B) or 20 wk   
(Fig. 4 C) in the ABIN1[D485N] knockin mice, demonstrating 
that some of the antibodies in the knockin mice were being 
However, the proportion of CD4+ and CD8+ T cells in the 
spleen was normal (Fig. S2 G).
It has been reported that an increased number of follicular 
helper T cell (Tfh cell) is associated with autoimmunity, and 
we therefore studied whether Tfh cell number was altered in 
the ABIN1[D485N] mice. These experiments revealed that 
the proportion of Tfh cells (CD4+ PD1hi and CXCR5+) in the 
spleen and LN was greatly increased (Fig. 3 E), as were the 
number  of  germinal  center  B  cells  (B220+  CD95+  and 
GL7+; Fig. 3 F). Consistent with more germinal center B cells, 
there was increased formation of germinal centers in the 
spleens of ABIN1[D485N] mice (Fig. 3 G). There was also an 
increase in the proportion of extrafollicular plasma cells in the 
spleen of ABIN1[D485N] mice (Fig. 3 H).
Figure 4.  Autoimmune phenotypes in 
ABIN1[D485N] mice. Values were compared 
by the Mann-Whitney U test. *, P ≤ 0.05; **,  
P ≥ 0.005; ***, P ≤ 0.005. (A) Serum levels of 
immunoglobulin isotypes quantitated by 
ELISA in WT and ABIN1[D485N] mice. Error 
bars represent mean ± SEM. (B) Level of anti-
dsDNA antibodies in serum of 16-wk-old WT, 
ABIN1[D485N], and heterozygous (HET) mice 
measured by ELISA. (C) Total antinuclear anti-
bodies (ANA; left) and anti-dsDNA antibodies 
(right) in the serum of 22-wk-old WT and 
ABIN1[D485N] mice were measured by ELISA. 
(B and C) Each symbol represents one mouse 
and the horizontal bars show the mean of the 
values obtained. (D) Kidney sections stained 
with fluorescein isothiocyanate–labeled anti–
mouse C3, C1q, and IgG. (E) Kidney sections 
stained with hematoxylin and eosin (top) or 
PAS (bottom). Bar, 0.05 mm. In the top panel, 
the arrowhead shows glomerulonephritis with 
capillary loop thickening by eosinophilic  
material and the black arrow shows infiltration 
of mesangium by neutrophils. In the bottom 
panel, the arrow shows glomerulonephritis, 
with capillary wall thickening by PAS-positive 
staining. (F–I) Hematoxylin and eosin–stained 
sections of spleen, heart, lungs, and liver.  
(F) Spleen. The arrow indicates the WT (left) or 
congested splenic artery in ABIN1[D485N] 
mice (right) by eosinophilic material. Bars,  
0.1 mm. (G) Heart. The arrow indicates infiltra-
tion of neutrophils and macrophages around 
arterial wall (A) in ABIN1[D485N] mice. M, 
myocardium. Bars, 0.2 mm. (H) Lungs. The 
arrows show plasma cells in the WT and 
ABIN1[D485N] mice. B, bronchus. Bars, 0.1 mm. 
(I) Liver, the portal tracts are shown by arrows. 
Bars, 0.1 mm. The data are from a single  
experiment with 7–9 (A–C) or 6–12  
(D–I) mice per genotype.1220 ABIN1 polyubiquitin binding prevents autoimmunity | Nanda et al.
and peripancreatic arteries (not depicted). 
The normal architecture of the walls of af-
fected splenic arterioles was largely replaced 
by fibrinous material with scattered nuclear 
debris and mononuclear inflammatory cells 
(fibrinoid necrosis), and by extravascular 
leakage  (Fig.  4  F).  Similar  changes  were 
noted in heart-base arteries but with more 
severe inflammatory cell infiltrates, includ-
ing neutrophils, macrophages, and reactive 
fibroblasts, which not only segmentally obliterated arterial wall 
architecture but also extended into the adjacent atrial myocar-
dium (Fig. 4 G). Similarly, in lung tissue of most mice, the peri-
bronchial lymphoid tissue was variably expanded by increased 
numbers of plasma cells (Fig. 4 H). Other histological lesions 
included expansion of hepatic portal tracts by variably (but 
often markedly) increased numbers of hematopoietic cells, 
lymphocytes, plasma cells, macrophages, and neutrophils with 
bridging fibrosis and biliary hyperplasia (Fig. 4 I).
The  combination  of  lesions  may  explain  why  all  the 
ABIN1[D485N] mice developed severe symptoms of auto-
immune disease, requiring them to be culled within 6 mo, if 
they had not died already. In contrast, no WT control mice 
had died at this age.
Enhanced proliferation, cytokine production, and activation 
of signaling pathways in B cells and myeloid cells, but not  
T cells, from ABIN1[D485N] knockin mice
To understand why abnormal levels of immunoglobulins 
were present in the serum, we studied B cell function in 
produced against self-cellular components, a feature of auto-
immune disease. The heterozygous ABIN1[D485N]+/ mice, 
which did not develop any pathological abnormalities, only 
had marginally elevated levels of anti-dsDNA (Fig. 4 B).
High levels of pathogenic immunoglobulins in the serum 
are known to be deposited in the kidney and the blood ves-
sels, initiating an inflammatory reaction in these organs. We 
found that there was immune complex deposition in the kid-
ney of the ABIN1[D485N] mice, leading to activation of the 
complement pathway (Fig. 4 D) and the development of 
severe renal disease at 20–24 wk of age. Histologically, this 
was revealed by severe generalized global membranoprolif-
erative glomerulonephritis of the kidney with infiltration of 
neutrophils and plasma cells (Fig. 4 E, top). There was also 
thickening of glomerular capillary loops and Bowman’s cap-
sule  basement  membrane  regions  by  periodic  acid-Schiff  
(PAS)–positive material (Fig. 4 E, bottom).
Vascular lesions were noted at the same age in multiple sites, 
including splenic arterioles (Fig. 4 F) and heart-base arteries 
(Fig. 4 G), with occasional involvement of Peyer’s Patch arterioles 
Figure 5.  Enhanced activation of B cells and 
myeloid cells in ABIN1[D485N] mice. (A) Naive 
purified splenic B cells from WT and ABIN1[D485N] 
mice were stimulated with 200 ng/ml LPS, 10 µg/ml 
LTA, 200 ng/ml of the TLR7 agonist R848, 10 µg/ml 
-IgM, or 1 µg/ml -CD40 for 72 h or left unstimu-
lated (control) before pulsing for a further 16 h with 
[3H]thymidine (0.5 µCi/well). [3H]thymidine incorpo-
ration into DNA was measured by harvesting and 
washing the cells followed by measurement of radio-
activity incorporated. (B) Flow cytometric analysis of 
surface expression of the activation marker CD86 
after stimulation of purified B cells with the agonists 
indicated. The filled histograms show results for WT 
cells and the empty histograms show the 
ABIN1[D485N] cells. (C) IL-6 and IL-12p40 secreted 
into the culture medium of B cells 48 h after expo-
sure to the agonists indicated. (D) IL-6 and TNF se-
creted into the culture medium of BMDC 24 h after 
exposure to 100 ng/ml LPS, 2 µg/ml LTA, 1 µg/ml 
Pam3CSK4, 1 µg/ml R848, or 1 µM of the TLR9 ago-
nist ODN 1826. Data are representative of five (A) or 
three (B–D) independent experiments with three to 
four mice of each genotype analyzed together. Error 
bars represent mean ± SD. *, P ≤ 0.05; **, P ≥ 0.005; 
***, P ≤ 0.005 (two-tailed Student’s t test).JEM Vol. 208, No. 6 
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more marked in the ABIN1[D485N] 
knockin  cells  (Fig.  5  B),  and  this 
might  contribute  to  the  increased 
activation of T cells via interaction 
with the CD28 receptor on T cells.
In contrast, stimulation of puri-
fied CD4+ T cells with anti-CD3, 
alone or in combination with either 
CD28 or IL-2, resulted in similar proliferation rates in WT 
and ABIN1[D485N] knockin cells (Fig. S3 A), and the pro-
duction of T cell cytokines tested was similar in different gen-
otypes (Fig. S3 B). There was also no effect of the knockin 
mutation on the expression of inducible co-stimulator (ICOS) 
or the T cell activation markers CD25 or CD69 after TCR 
stimulation (unpublished data), again indicating that the in-
creased proportion of activated T cells and Tfh cells may not 
be explained by a T cell–intrinsic defect. Collectively, these 
results indicated that the T cell phenotypes observed in the 
ABIN[D485N] mice may not have been caused by an intrin-
sic alteration in T cell receptor signaling. It has been well 
documented that regulatory T cells (T reg cells) play an im-
portant role in autoimmunity by limiting the activation of   
T cells, and that a decreased T reg cell number can cause auto-
immunity. However, the proportion of T reg cells in the 
the mutant mice because these cells are major producers of 
  immunoglobulins in vivo. Using purified naive B cells from 
the spleens of 5–6-wk-old mice before the onset of spleno-
megaly, we found that the TLR4 agonist LPS, the TLR2/6 
agonist lipoteichoic acid (LTA), and the TLR7 agonist R848, 
as well as anti-IgM and anti-CD40, stimulated B cell prolifer-
ation more strongly in the ABIN1[D485N] mice than in 
the WT mice (Fig. 5 A). In contrast, the B cells from WT and 
ABIN1[D485N] mice proliferated similarly in response to 
the TLR9 ligand ODN1826 (unpublished data). The in-
creased proliferation of B cells in response to anti-IgM and 
anti-CD40 was not explained by differences in the expression 
of these receptors, which were similar in ABIN1[D485N] and 
WT mice (unpublished data). The stimulation of B cells 
with either TLR agonists or anti-CD40 also increased the 
expression of the co-stimulatory molecule CD86, which was 
Figure 6.  Activation of signaling path-
ways in B cells and BMDC from WT and 
ABIN1[D485N] mice. (A–C) B cells from WT 
and ABIN1[D485N] mice were stimulated 
with 0.5 µg/ml of the TLR7 agonist R848  
(A), 10 µg/ml -IgM (B), or 10 µg/ml -CD40 
(C) for the times indicated, and cell lysates 
were probed with the antibodies indicated.  
*, nonspecific band. Antibodies that recognize 
GAPDH and p38 MAPK served as loading 
controls. The -phospho (p)–IKK-/ anti-
body in C–E (Ser176/180, antibody 16A6; Cell 
Signaling Technologies) differed from that 
used in A and B (Ser180/181; Cell Signaling 
Technologies). (D and E) BMDC from WT and 
ABIN1[D485N] mice were stimulated with 
0.25 µg/ml of the TLR7 agonist R848 (D) or  
2 µg/ml of the TLR2/6 agonist LTA (E) for the 
times indicated, and cell lysates were probed 
with the antibodies indicated. (A–E) The data 
are representative of two to four indepen-
dent experiments. (F) BMDC were stimulated 
with 0.5 µg/ml R848 for the times indicated 
and lysed, and TAK1 was immunoprecipitated 
with -TAK1 and assayed as described in 
Materials and methods. The activity is plotted 
as fold increase compared with that mea-
sured in the lysates from cells not been stim-
ulated with R848. The results are average 
data from three different experiments, each 
with BMDC from different mice, with each 
sample being assayed in duplicate. Error bars 
represent mean ± SEM.1222 ABIN1 polyubiquitin binding prevents autoimmunity | Nanda et al.
ABIN1[D485N] mice was only slightly higher than that in 
WT mice (Fig. S3 C).
The stimulation of B cells with LPS alone, or the combi-
nation of LPS with anti-CD40, also induced higher levels of 
IL-6 and IL-12p40 secretion in the ABIN1[D485N] mice 
compared with WT mice. Similar results were found with 
LTA and R848 (Fig. 5 C). Moreover, TLR stimulation of 
other immune cells of myeloid origin, such as BM-derived 
DCs (BMDCs), also increased production of IL-6 and other 
proinflammatory cytokines, such as TNF, more markedly in 
the cells from the ABIN1[D485N] mice (Fig. 5 D).
The results described in the previous paragraph sug-
gested that signaling events required for the production of 
cytokines by B cells and myeloid cells were being switched 
on more strongly in the ABIN1[D485N] mice compared 
with WT, and they led us to examine the activation of these 
pathways. Stimulation of naive splenic B cells with the TLR7 
ligand R848 (Fig. 6 A), the TLR4 ligand LPS (Fig. S4 A), the 
B cell receptor (BCR) ligand (anti-IgM; Fig. 6 B), or the 
CD40  agonist  (anti-CD40;  Fig.  6  C)  caused  enhanced 
phosphorylation (activation) of the canonical IKKs (IKK-
/) and the phosphorylation of their substrates p105/ 
NF-B1 and IB in the ABIN1[D485N] mice compared 
with WT mice, and, consistent with enhanced phosphory-
lation of IB, there was a more rapid proteasomal degra-
dation of this protein. There was also modestly enhanced 
phosphorylation (activation) of the MAPKs JNK1/2 and 
p38 MAPK. Enhanced activation of the canonical IKKs 
and MAPKs was also observed in BMDC and BMDM from 
ABIN1[D485N] mice compared with WT mice after stim-
ulation with LTA or the TLR7 agonist R848 (Fig. 6, D and E; 
and Fig. S4, B and C).
The finding that activation of MAPKs, as well as the 
canonical IKK complex, was enhanced in immune cells from 
the ABIN1[D485N] mice after TLR stimulation indicated 
that ABIN1 must be exerting its effect by suppressing the 
activation of a more upstream component of the pathway. 
This led us examine the activation of TAK1 and to show that 
it is also enhanced in BMDC from the knockin mice com-
pared with WT mice (Fig. 6 F).
Enhanced activation of the nucleotide oligomerization 
domain (NOD) 1–NOD2 signaling pathway
The cytoplasmic proteins NOD1 and NOD2 detect peptido-
glycan components from intracellular bacteria that have evaded 
the TLR defense system (Inohara et al., 2005). The activation 
of these receptors induces their interaction with the protein 
kinase RIP2, leading to the activation of NF-B, MAPKs, and 
inflammatory mediators by a pathway that appears to inter-
sect with the TLR signaling pathway at the level of TAK1 
(Windheim et al., 2007). We found that the peptidoglycan-
stimulated activation of NOD1 (Fig. S4 D) and NOD2 
Figure 7.  Comparison of the phenotypes of WT, ABIN1[D485N], 
ABIN1[D485N]/MyD88/, and MyD88/ mice. (A) Spleen sizes of 
WT, ABIN1[D485N]xMyD88+/+, ABIN1[D485N]xMyD88/, and MyD88/ 
mice. Bar, 1 cm. A typical result from many mice analyzed is shown.  
(B) Flow cytometric analysis was performed as in Fig 2, and a representative 
set of contour plots is presented (top) showing the proportion of germinal 
center (GC) B cells (B220+ GL-7+ CD95+) in WT, ABIN1[D485N]xMyD88+/+, 
ABIN1[D485N]xMyD88/, and MyD88/ mice. Similar results were  
obtained in three independent experiments. On the bottom, the percentage  
of GC B cells is shown for each WT type (filled squares), 
ABIN1[D485N]xMyD88+/+ (filled triangles), ABIN1[D485N]xMyD88/ 
(open triangles), and MyD88/ (open squares) mouse examined. Each 
symbol represents an individual mouse and the horizontal bar shows the 
mean of the values obtained. (C) Anti-dsDNA antibodies and ANA anti-
bodies in ABIN1[D485N]xMyD88+/+ mice (filled squares) and 
ABIN1[D485N]xMyD88/ mice (filled triangles). Data are shown for a 
single experiment with six to eight mice of each genotype. ***, P < 0.005; 
**, P > 0.005 (Mann-Whitney U test). Each symbol represents an individual 
mouse and the horizontal bar shows the mean of the values obtained.  
(D) Hematoxylin and eosin (H&E) staining (first two panels) and PAS 
staining (third and fourth panels) of kidney sections from 
ABIN1[D485N]xMyD88+/+ and ABIN1[D485N]xMyD88/. Bars, 0.05 mm. 
The arrow shows PAS-positive material. Three or four mice of each geno-
type were analyzed and a representative result is shown.
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had a similar phenotype to the ABIN1[D485N] mice (Fig. S6 B), 
although it was slightly more severe, in as much as the mice be-
came moribund about a month earlier than the ABIN1[D485N] 
mice. As found in the ABIN1[D485N] mice, there was en-
hanced activation of TLR signaling pathways in BMDM from 
the ABIN1[478-606] mice (Fig. S6 A).
TNF-induced apoptosis in embryonic fibroblasts  
from ABIN1[D485N] mice
ABIN1/ mice were reported to be found at normal Men-
delian ratios up to E18.5, but the embryos then died during 
late embryogenesis from fetal liver apoptosis and hypoplasia. 
Embryonic fibroblasts isolated from the ABIN1/ mice were 
hypersensitive to TNF-induced apoptosis, and the lethality 
could be rescued by crossing to mice that did not express the 
TNFR1 receptor (Oshima et al., 2009). The TNF-stimulated 
apoptosis could be restored to normal levels by reintroducing 
WT ABIN1 but not by reintroduction of the ABIN1[D485N] 
mutant. Consistent with these findings, we found that embry-
onic fibroblasts from the ABIN1[D485N] knockin mice also 
showed enhanced TNF-induced apoptosis (Fig. S7, C and D). 
The reason why the ABIN1[D485N] and the ABIN1[478-
606] mice that we generated did not display embryonic le-
thality is unclear but could be the result of a difference in the 
background of the mice.
In contrast to the effect of TNF on apoptosis, the TNF-
stimulated activation of NF-B was reported to be similar in 
embryonic fibroblasts from ABIN1/ mice and WT mice 
(Oshima et al., 2009). Consistent with this finding, we did not 
see enhanced activation of MAPKs or the canonical IKK 
complex in embryonic fibroblasts from the ABIN1[D485N] 
mice, although these signaling pathways were activated a 
little more strongly in IL-1–stimulated fibroblasts from the 
ABIN1[D485N] mice (Fig. S7).
DISCUSSION
In this paper, we demonstrate that replacing a single aspartate 
in the UBAN of ABIN1 (Asp485) by an asparaginyl residue, 
which suppresses the binding of ABIN1 to K63-pUb chains 
or linear pUb chains, causes autoimmunity in mice. Immune 
cells from the ABIN1[D485N] knockin mice showed en-
hanced activation of signaling pathways in response to TLR 
agonists that signal via MyD88, leading to increased B cell 
proliferation and enhanced production of IL-6 and IL-12p40 
production by B cells and elevated IL-6 and TNF by myeloid 
cells. The critical role of TLR signaling pathways in driving 
autoimmunity was indicated by the finding that the pheno-
type was suppressed completely when the ABIN1[D485N] 
knockin mice were crossed to MyD88/ mice. These obser-
vations raised the question of how increased signaling via 
TLR–MyD88 pathways can lead to autoimmunity.
Autoimmunity  probably  results  from  the  formation  of 
many germinal centers that were present in the spleens of the 
ABIN1[D485N] mice and are responsible for antibody isotype 
switching and the production of pathogenic antibodies. As 
suggested by others (Vinuesa et al., 2005, 2009), the formation 
(not depicted) induced a far stronger activation of IKK-/ 
and  MAPKs  in  BMDM  from  the ABIN1[D485N]  mice 
than WT mice.
The absence of MyD88, but not RIP2, suppresses  
the autoimmune phenotype of ABIN1[D485N] mice
The results presented in the previous section suggested that 
enhanced activation of one or more cell signaling pathways 
might underlie or contribute to the autoimmune phenotype 
of the ABIN1[D485N] mice. To investigate the importance of 
the TLR-MyD88–dependent and NOD1/2–RIP2 signaling 
pathways, we crossed the ABIN1[D485N] mice with mice that 
do not express the adaptor MyD88 (required for  TLR-MyD88 
signaling) signaling or with mice that do not express RIP2. 
The ABIN1[D485N]xRIP2/  mice  still  displayed  all  the 
gross phenotypes of the ABIN1[D485N] mice (splenomegaly, 
lymphadenopathy, and intestinal nodules) and flow cytom-
etry analysis did not show rescue of any immune phenotype 
(unpublished data). The ABIN1[D485N]xMyD88/ mice, 
however, did not develop splenomegaly (Fig. 7 A), enlarged 
LNs, and intestinal nodules (not depicted). They had greatly 
reduced numbers of germinal center B cells in the spleen   
(Fig. 7 B), and serum levels of anti-dsDNA, antinuclear anti-
bodies (Fig. 7 C), and different immunoglobulins (not depicted) 
were also greatly reduced in the ABIN1[D485N]xMyD88/ 
mice. Moreover, no glomerulonephritis was observed in the 
kidneys of the ABIN1[D485N]xMyd88/ after 20–24 wk 
(Fig. 7 D). Interestingly, the increased number of activated   
T cells and Tfh cells in the ABIN[D485N] mice also returned to 
the level found in WT mice in the ABIN1[D485N]xMyD88/ 
mice (Figs. S5, A and B).
CD40 is not thought to signal via MyD88 (He et al., 
2010a), but using B cells from age-matched ABIN1[D485N] 
mice, MyD88/ mice, ABIN1[D485N]/MyD88/ mice, 
and WT mice, we found that the enhanced activation of the 
canonical IKKs and JNK observed in CD40-stimulated B cells 
from the ABIN1[D485N] mice was reduced in B cells from 
the ABIN1[D485N]/MyD88/ mice to the same level found 
in either WT mice or MyD88/ mice (unpublished data). 
This suggests that the over-reactivity of the ABIN1[D485N]-
expressing B cells to CD40 depends on MyD88 signaling. 
This suggests that there may be cross talk between the CD40 
and MyD88 signaling pathways, which would be interesting 
to investigate in future studies.
Generation of ABIN1[D478-606] mice
The way in which the targeting vector for the ABIN1[D485N] 
mice was designed allowed the targeted region to be removed 
by crossing to CRE deleter mice, which generated a form of 
ABIN1 in which residues 478–606 were deleted. This deletion 
did not cause the truncated protein to misfold and be de-
graded, and the ABIN[478-606] mutant was actually ex-
pressed at higher levels than WT ABIN1 in BMDM (Fig. S6 A) 
and embryonic fibroblasts (not depicted). The ABIN1[478-
606] mice were also born at near Mendelian frequencies and 1224 ABIN1 polyubiquitin binding prevents autoimmunity | Nanda et al.
78.55 ± 31.57 kU/ml (n = 5), respectively, in control and   
antibiotic-fed ABIN1[D485N] mice. Moreover, the antibiotic-
fed ABIN1[D485N]  mice  had  similar  enlargement  of  the 
spleen and LNs. In contrast, the control IL-10/ mice, which 
were fed the same combination of antibiotics in parallel, were 
protected against the development of ulcerative colitis and 
anal prolapse, as expected.
How  polyubiquitin  binding  to WT ABIN1  limits  the 
strength of TLR-MyD88 signaling is a complex issue and a 
full  molecular  understanding  will  require  further  analysis. 
However, the studies we have performed in this paper indi-
cate that ABIN1 exerts its inhibitory effects downstream of 
MyD88 but upstream of TAK1, explaining why the activation 
of JNK and p38 MAPK, as well as the canonical IKKs, is 
enhanced in immune cells from the ABIN1[D485N] mice. 
Enhanced activation of TAK1 can also explain why the 
NOD1/2–RIP2 signaling pathway was activated more strongly 
in  peptidoglycan-stimulated  BMDM  from  ABIN1[D485N] 
mice and why B cells from the mutant mice proliferated more 
rapidly than B cells from the WT mice in response to BCR 
and CD40 agonists because TAK1 is known to be required 
for  NOD1/2-RIP2  (Windheim  et  al.,  2007),  BCR,  and 
CD40 signaling (Sato et al., 2005).
ABIN1 was originally identified as a protein that interacts 
with the deubiquitylase A20. Like ABIN1, A20 is known to 
function as a negative regulator of the innate immune system and 
mice with a conditional knockout of A20 in B cells develop   
autoimmunity (Boone et al., 2004; Tavares et al., 2010; Chu   
et al., 2011). Moreover, human polymorphisms in A20 pre-
dispose to autoimmune diseases (Plenge et al., 2007; Thomson 
et al., 2007; Nair et al., 2009). A priori, one might therefore 
have imagined that by binding to K63-pUb chains/proteins 
generated in response to TLR activation (see Introduction), 
ABIN1 may recruit A20 to its substrates, facilitating the 
A20-catalysed  hydrolysis  of  K63-pUb  chains/proteins  and 
the inhibition of TLR-MyD88–dependent signaling. Cells 
expressing the polyubiquitin binding–defective ABIN1[D485N] 
mutant would be unable to perform this function, leading to 
increased levels of K63-pUb chains/proteins and enhanced 
recruitment and activation of the TAK1 complex. However, 
whether this is the way in which ABIN1 limits the strength of 
signaling is unclear for several reasons. First, the bacterially 
expressed A20 catalytic domain cleaves K48-pUb chains and 
not K63-pUb chains or linear polyubiquitin chains in vitro 
(Komander et al., 2009), although A20 may be able to hydro-
lyze  K63-pUb  chains  when  overexpressed  in  mammalian 
cells (Wertz et al., 2004), in which case there may be a mecha-
nism for altering the specificity of A20 in vivo. Second, a 
truncated form of ABIN1, ABIN1[444–601], which does 
not interact with A20, inhibits TNF-stimulated NF-B– 
dependent gene transcription as effectively as WT ABIN1 
in overexpression experiments (Heyninck et al., 2003). Third, 
the level of A20 is low in unstimulated cells and increases 
greatly after stimulation for 1 h with TLR agonists (Fig. 6, C 
and D), but the enhanced activation of signaling pathways in 
immune cells from the ABIN1[D485N] mice can be observed 
of germinal centers may be triggered by the presence of ab-
normally high numbers of Tfh cells, which was a feature of the 
spleen and LNs of the ABIN1[D485N] knockin mice. An in-
crease in the number of Tfh cells can result from the aberrant 
expression of ICOS molecules on T cells (Vinuesa et al., 2005) 
and be stimulated by IL-6 and IL-12 (Nurieva et al., 2008;   
Ma et al., 2009; Schmitt et al., 2009). We did not observe any 
changes in T cell receptor activation or increased production 
of ICOS by T cells in the ABIN1[D485N] mice compared 
with WT mice after TCR stimulation. It therefore seems more 
likely that increased IL-6 and IL-12 secretion in B cells and 
myeloid cells via the TLR–MyD88 pathway, coupled with 
increased expression of co-stimulatory molecules (CD80 and 
CD86) by antigen-presenting cells, underlies the increased 
number of Tfh cells in the mutant animals. Enhanced TLR 
signaling could, however, lead to germinal center formation 
in other ways. For example, the migration of B cells to form 
new germinal centers can be driven by stimulation of TLR4 
(Hwang et al., 2009) or TLR7 (Bessa et al., 2010) in vivo, even 
in IL-21/ mice where Tfh cell function is defective. Another 
potentially  important  mechanism  by  which TLR-MyD88 
signaling pathways contribute to autoimmunity is via the   
hyperactivation of T reg cells, leading to loss of their ability to 
suppress effector T cell responses (Pasare and Medzhitov, 2004; 
Peng et al., 2005; Sutmuller et al., 2007). In summary, our stud-
ies with the ABIN1[D485N] mice provide striking support for 
the concept that abnormally high TLR-MyD88 signaling can 
trigger autoimmunity (Marshak-Rothstein, 2006).
The increased production of interferon  in plasmacytoid 
DCs by TLR7 and/or TLR9 agonists is reported to be involved 
in the development of lupus-like autoimmunity (Banchereau 
and Pascual, 2006), raising the question of whether ABIN1 
prevents autoimmunity by limiting TLR7/TLR9-stimulated 
interferon  production by pDC. However, we were unable 
to detect any increase in interferon  production by pDCs 
from ABIN1[D485N] mice compared with pDCs from WT 
mice in response to the TLR7 agonist poly(dU) or the TLR9 
agonist ODN1826 (unpublished data).
An important unresolved question is the identity of the 
endogenous ligands that initiate activation of the TLR–MyD88 
pathways in these animals in vivo. One possibility is that en-
dogenous host RNA and/or DNA is able to activate TLR7 
and TLR9 in the ABIN1[D485N] mice but not in WT mice. 
Alternatively, components of commensal bacteria may activate 
the TLR–MyD88 pathways resulting in autoimmunity, as ob-
served in mice that do not express TANK (TRAF-associated 
NF-B activator), which also display enhanced activation of 
NF-B in response to ligands that signal via the TLR–MyD88 
dependent pathway (Kawagoe et al., 2009). To investigate 
whether commensal bacteria were involved in the develop-
ment of the phenotype, we fed the mice from birth with 
broad spectrum antibiotics, but this had no effect on the phe-
notype. The level of anti-dsDNA in the serum after 16 wk 
was 20.47 ± 3.69 kU/ml (n = 8) and 19.42 ± 8.19 kU/ml 
(n  =  9),  respectively,  in  control  and  antibiotic-fed WT 
mice,  and  rose  to  61.54  ±  33.26  kU/ml  (n  =  8)  and   JEM Vol. 208, No. 6 
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MATERIALS AND METHODS
Expression and purification of ABIN1 and NEMO and binding to 
polyubiquitin. Human ABIN1 and ABIN1[D472N] were cloned and 
expressed as fusion proteins with glutathione S-transferase (GST) at the   
N terminus and a His6 tag at the C terminus. The expressed proteins   
were purified on nickel-nitrilotriacetate agarose (QIAGEN) followed by 
chromatography on glutathione-Sepharose (GE Healthcare). Human NEMO 
and NEMO[D311N] were expressed as GST fusions and purified on gluta-
thione-Sepharose. 8 µg of these proteins were immobilized individually on   
a 10-µl packed volume of glutathione-Sepharose and incubated for 1 h at 
21°C with 2 µg of K48-linked, K63-linked (Boston Biochem), or linear 
ubiquitin oligomers (Enzo Life Sciences) in 300 µl 25 mM HEPES, pH 7.5, 
1 mM EGTA, 0.5% (vol/vol) Triton X-100, and 2 mM MgCl2 (Buffer A) 
plus 150 mM NaCl. The beads were washed five times with Buffer A plus 
250 mM NaCl and once with Buffer A without Triton X-100.
Generation  of  ABIN1[D485N]  knockin  mice. The Asp485 to Asn 
knockin mutation was generated in exon 14 of the ABIN1 locus and, at the 
same time, LoxP sites were inserted in the introns adjacent to exons 14 and 
16 by standard gene targeting methods (Fig. S1 A). The following primers 
were used for making the targeting vector (underlined regions indicate the 
presence of introduced restriction sites or LoxP sequences): 5 arm sense 
(5-GAGCGGCCGCCAGACCTTTTAAAAACATATCTGCTAACAA-
TACAGTTG-3),  5  arm  antisense  (5-AGGCCGGCCAAAGGAT-
CCATAACTTCGTATAGCATACATTATACGAAGTTATCGAGCCC-
CAAATCCAACTTTACCAG-3), Exon14-16 sense (5-AGGATCCGGT-
GCCCTACTCAAATCTCCAATGC-3), exon 14–16 antisense (5-AGGC-
CGGCCATAACTTCGTATAGCATACATTATACGAAGTTATAGC-
TGGAGACCTGGTGGCAGTCCTG-3), splice donor sense (5-AACC-
GGTGTGCCATGCCAGCCATGGTACCTCACCATG-3), splice donor 
antisense  (5-TACCGGTTAATTAACATATGTAGCTGGAGACCTG-
GTGGCAGTCCTG-3), 3 arm sense (5-TGGCGCGCCATATGG-
AGTACCATCGGCTGCCGAGTCAGCTC-3), and 3 arm antisense 
(5-ACTCGAGTCGACGATCCCTGATCTCTTGCCTCCTCCAC-3).
Primers used for screening and routine genotyping are as follows: P1   
5 LoxP sense (5-ATCCAACTCTCCAGCCAATAACC-3), P2 5 LoxP 
antisense  (5-GAGGCGTGTGGAAGTCTGC-3),  P3  mRNA  sense   
(5-CGTTGTGAGTTGGATAGTTGTGG-3),  P4  mRNA  antisense   
(5-AGCTGGCTCTGAAAGATGAAGG-3), P5 3 LoxP sense (5-CCTA-
TCCCTATGCCTACCCACCCATG-3), P6 3 LoxP antisense (5-AGC-
TGACTCGGCAGCCGATGGTACTC-3),  and  P7  neo-IRES  sense 
(5-CGTATTCAACAAGGGGCTGAAGGATGC-3).  All  animals  were 
maintained in specific pathogen-free conditions consistent with EU and UK 
regulations. All the work was performed under a UK Home Office project 
license that was awarded after recommendation by the University of Dundee 
Ethical Review Committee. The ABIN1[D485N] mice generated were on 
a 129SvJ × C57BL/6 background and were backcrossed two generations to 
C57BL/6. MyD88/ mice were provided by S. Akira (Osaka University, 
Osaka, Japan) and RIP2/ mice were obtained from R.A. Flavell (Yale 
  University School of Medicine, New Haven, CT).
Flow  cytometry.  Single-cell  suspensions  were  made  from  thymus  and 
spleen by gentle sieving and pipetting, whereas BM samples were prepared 
by flushing them out from tibia and femur with PBS. Peritoneal lavage was 
collected by injecting 10 ml PBS into the peritoneum. Erythrocytes were re-
moved from spleen, BM, and peritoneal lavage by treatment with red blood 
cell lysis buffer (Sigma-Aldrich). For surface staining, cells were washed twice 
with ice-cold PBS, 2% (wt/vol) BSA, and 0.1% (wt/vol) sodium azide. 106 
cells were blocked for 15 min with FcR antibody (purified CD16/32; 2.4G2; 
BD) and incubated for 30 min at 4°C with various antibodies conjugated to 
FITC,  phycoethrythrin  (PE),  PE-Cy5  (Tricolor), APC,  or APC-Cy7  for 
multiple color fluorescence surface staining. For analysis of various cell types, 
cell surface markers examined included (with clone numbers in parentheses) 
Thy1.2 (53–2.1), CD45R (B220; RA3-6B2), CD4 (RM4-5), CD8 (53–
6.7), TCR-  (H57-597),  CD86  (GL1),  MHC  II  (M5/114.15.2),  CD44 
after only 10–15 min (Fig. 6), demonstrating that this effect is 
independent of the induction of A20. Fourth, although the   
B cell–specific knockout of A20 leads to autoimmunity, the 
onset of the pathology seems to be delayed by several months 
compared  with  the ABIN1[D485N]  mice  (Tavares  et  al., 
2010). Therefore, if the phenotype of the ABIN1[D485N] 
mice is driven only by alterations in B cell function, it 
would be difficult to explain this solely by the loss of ABIN1-
dependent recruitment of A20 to its substrates.
ABIN1  binds  linear  polyubiquitin  chains,  as  well  as   
K63-polyubiquitin chains (Fig. 1), and LUBAC, an E3 ligase 
which produces linear polyubiquitin specifically in vitro,   
appears to participate in at least one MyD88-dependent 
signaling pathway because the IL-1–stimulated activation of 
the canonical IKK complex was reported to be impaired in 
MEFs  deficient  in  HOIL-IL,  a  component  of  LUBAC 
(Tokunaga et al., 2009). Therefore, the possibility that ABIN1 
restricts signaling to NF-B by binding to linear polyubiq-
uitin chains as well as, or instead of, K63-pUb chains cannot 
be excluded at this stage. However, the activation of JNK by 
TNF was not inhibited in HOIL-IL/ MEFs, implying 
that LUBAC is not required for the activation of TAK1. 
Moreover,  the TAB2  component  of  the TAK1  complex 
binds to K63-pUb tetramers >100-fold more strongly than 
to linear ubiquitin tetramers (Kanayama et al., 2004; Kulathu 
et al., 2009; Sato et al., 2009). WT ABIN1 might therefore 
compete  with  the  polyubiquitin-binding  components  of 
the TAK1 complex (TAB2–TAB3) for binding to the same 
K63-pUb chains/proteins, limiting the extent of activation 
of TAK1. We also observed in the present study that the 
endogenous polyubiquitylated IRAK1 could be coimmuno-
precipitated with WT ABIN1, but not with ABIN1[D485N], 
from  the  extracts  of  LPS-stimulated  BMDM. Therefore,   
another  possibility  is  that  the  interaction  of WT ABIN1 
with polyubiquitylated IRAK1 may hinder the ability of 
IRAK1 to interact with and activate TRAF6, reducing the 
TRAF6-mediated formation of K63-pUb chains and limit-
ing the activation of TAK1. IRAK1 undergoes Lys63-linked 
polyubiquitylation in response to IL-1 (Windheim et al., 
2008), but the possibility that it also undergoes linear poly-
ubiquitylation has not been excluded.
Interestingly, while this study was in progress, human 
polymorphisms were identified in the gene encoding ABIN1 
that predispose to lupus-like autoimmune diseases, psoria-
sis (Han et al., 2009; Nair et al., 2009), and vasculitis (He   
et al., 2010b). This suggests that ABIN1 also plays a key role 
in preventing autoimmunity in man. The ABIN1[D485N] 
mice may therefore be a good model for human autoimmune 
disease and could be used to assess the efficacy of drugs that 
target components of TLR–MyD88 signaling pathways. 
Drugs that increase the expression of ABIN1 could also 
have therapeutic value because the adenovirus-mediated 
delivery of ABIN1 to the lung epithelium has been re-
ported to reduce allergen-induced eosinophil infiltration 
of the lungs in a mouse model of allergen-induced asthma 
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After mixing end over end for 60 min with 15 µl of protein G–Agarose 
beads, the agarose was collected and washed six times with cell lysis buffer 
plus 0.5 M NaCl. Immunoprecipitates were denatured in SDS, subjected to 
SDS-PAGE, and immunoblotted.
Antibodies  for  immunoblotting  and  immunoprecipitation. Sheep 
antibodies against mouse ABIN1 (sheep number S345C, third bleed) and   
human TAK1 (sheep number S828A, first bleed) were generated in the MRC 
Protein Phosphorylation Unit by J. Hastie (University of Dundee, Dundee, 
UK). Antibodies that recognize IKK-/ phosphorylated at Ser180/Ser181 
or Ser 176/180, p105/NF-B1 phosphorylated at Ser933, p38 MAPK phos-
phorylated at the TGY motif, ERK1/ERK2 phosphorylated at the TEY 
motif, IB phosphorylated at Ser32/36, and antibodies that recognize the 
deubiquitylase A20, all forms of p38 MAPK, ERK1/ERK2, IB, Caspase8, 
and Caspase3 were obtained from Cell Signaling Technology. JNK phos-
phorylated at the TPY motif was from Invitrogen. Mouse monoclonal anti-
bodies  against  GAPDH  (Abcam)  and  ubiquitin  (P4D1;  Santa  Cruz 
Biotechnology, Inc.), anti-IRAK1 (Santa Cruz Biotechnology, Inc.), and 
rabbit-,  mouse-,  and  sheep-specific  secondary  antibodies  conjugated  to 
horseradish peroxidase (Thermo Fisher Scientific) were purchased from the 
suppliers in parentheses.
Measurement of TAK1 activity. This was performed as described previ-
ously (Cheung et al., 2003), except that -TAK1 was used to immuno-
precipitate TAK1 instead of -TAB1. In brief, TAK1 complexes were 
immunoprecipitated from 0.15 mg BMDC extract protein, using 0.45 µg 
anti-TAK1 antibody. The TAK1 activity in the immunoprecipitates was mea-
sured by the activation of MAPK kinase 6 and coupled to the activation of 
p38 MAPK. The active p38 MAPK generated in this step was quantified 
in a second assay by measuring its ability to incorporate [32P]-phosphate from 
-[32P]ATP into myelin basic protein.
Statistical analysis. Statistical significance was calculated either using the 
two-tailed Student’s t test or the Mann-Whitney U test using Prism software 
(GraphPad Software). Further details are provided in the relevant figure legends.
Online  supplemental  material. Fig. S1 shows design of the targeting 
vector and the expression pattern of ABIN1 protein in various cells from 
ABIN1[D485N] mice. Fig. S2 shows immune phenotyping of ABIN1[D485N] 
mice. Fig. S3 shows no alteration in T cell receptor signaling in ABIN1 
knockin mice. Fig. S4 shows enhanced activation of LPS signaling in B cells 
and also enhanced activation of TLR-MyD88 and NOD1-RIP2 signal-
ing pathways in BMDM from ABIN1[D485N] mice. Fig. S5 shows rescue of 
the T cell phenotype observed in ABIN1[D485N]/MyD88/ mice. Fig. S6 
shows enhanced activated of TLR signaling in BMDM from ABIN1[478-606] 
mice, the phenotype of ABIN1[478-606] mice, and enhanced TNF-induced 
apoptosis in embryonic fibroblasts from ABIN1[D485N] mice. Fig. S7 shows 
TNF and IL-1 signaling in embryonic fibroblasts from ABIN1[D485N] mice.   
Online supplemental material is available at http://www.jem.org/cgi/content/ 
full/jem.20102177/DC1.
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(IM7), CD62L (MEL-14), CD69 (H1.2F3), CD138 (syndecan-1, 281–2), 
CD40 (3/23), CD43 (S7), Gr-1 (Ly6C/G; RB6-8C5), CD11c (HL3), CD5 
(53–7.3), CD21 (7G6), CD23 (B3B4), CD25 (PC61.5), IgM (II/41), CXCR5 
(2G8), PD-1 (J43), and GL-7 CD95 (Jo2; all antibodies were obtained from 
BD).  CD11b  and  F4/80  antibodies  were  obtained  from  Invitrogen. The 
mouse T reg cell detection kit (FJK-16s) was obtained from eBioscience. 
Data were acquired with a FACSCalibur (BD) flow cytometer with Cell 
Quest software. Results were analyzed with FlowJo software (Tree Star).
Histopathology  and  immunohistochemistry.  Formalin-fixed  tissues 
were stained with hematoxylin & eosin or with the PAS reagent. For immuno-
histochemical labeling of germinal centers, sections were dewaxed in xylene 
and rehydrated through graded alcohols. Proteinase K (Dako) was applied for 
20 min at 20°C for antigen retrieval, and slides were washed in buffer and a 
peroxidase blocker applied (Dako) for 5 min, followed by further washes. The 
slides were incubated for 1 h with biotinylated peanut agglutinin (Vector 
Laboratories) diluted 1:100. After washing, Avidin-Biotin Complex was ap-
plied for 30 min, washed again, and visualized by incubation for two 5-min 
periods in diaminobenzidine (Dako). After further washing, counterstaining 
was performed for 30 s using Gill’s hematoxylin. Stained sections were 
washed, dehydrated, and mounted under glass coverslips with DPX. For   
immunofluorescence studies, kidney sections were washed three times in 
PBS and blocked for 30 min at 20°C with 2.5% horse serum, 1% BSA, 0.05% 
Tween 20, and 0.05% Triton X-100. Sections were washed three times in 
PBS and mounted with Vectashield. FITC conjugated anti–mouse C3 
(CL7503F; Cedarlane Laboratories Limited), C1q (JL-1; Hycult Biotech), 
and IgG (F2266; Sigma-Aldrich) were used for immunostaining. Images were 
taken on a microscope (BX51; Olympus) with a camera (DP71; Olympus) 
fitted using acquisition software (Olympus). Images were processed with 
Photoshop software (CS3; Adobe).
Measurement of autoantibodies and immunoglobulin isotypes by 
ELISA. Blood was collected from mice by cardiac puncture, allowed to clot, 
and the serum was separated by centrifugation. Immunoglobulins (Immunol-
ogy Consultants Laboratory) and autoantibodies to dsDNA and antinuclear 
antibodies (total Ig; Alpha Diagnostics International) were measured by ELISA.
Multiplex  cytokine  assays. Cytokines in cell culture supernatants and 
mouse serum were measured using either Luminex-based Bio-Plex Mouse 
Grp 1 Cytokine 8-Plex, 6-Plex Panel, or 13 plex (Bio-Rad Laboratories) or 
individual Bioplex cytokine kits.
B cell and T cell proliferation. Untouched naive splenic B cells of >98% 
purity were isolated using a B cell isolation kit (Miltenyi Biotec) and 105 cells 
were cultured for 72 h in 96-well plates with LPS and LTA, R848, anti-IgM 
(Jackson ImmunoResearch Laboratories, Inc.), or anti-CD40 (Clone 3/23; 
BD). Splenic and LN CD4+ T cells (>95% pure) were isolated using a CD4+ 
T cell isolation kit (Miltenyi Biotech) and stimulated for 72 h with plate-
bound anti-CD3 alone (clone 145-2C11; BD) or with anti-CD3 plus anti-CD28 
(37.51; BD). The samples were pulsed for 16 h with 0.5 µCi [3H]thymidine   
before harvesting and measuring [3H]thymidine incorporation.
Generation of BMDM and BMDC. BMDM and BMDC were obtained 
by differentiating femur and tibia BM using recombinant mouse M-CSF 
(R&D Systems) and GM-CSF (R&D Systems), respectively. After 12–24 h of 
replating, cells were stimulated with LPS (Escherichia coli strain O5:B55; Enzo 
Life Sciences), LTA from Staphylococcus aureus, Pam3CSK4, CpG DNA (ODN 
1826), or R848 (TLR7 agonist), all obtained from InvivoGen. For immuno-
precipitation and immunoblotting, cell extracts were prepared as previously 
described (Windheim et al., 2008).
Immunoblotting and immunoprecipitation. 10 µg of cell extract pro-
tein was subjected to SDS-PAGE and immunoblotting as previously de-
scribed (Windheim et al., 2008). To immunoprecipitate ABIN1, 1.0 mg of 
cell extract protein was incubated for 2 h with 0.5 µg of the ABIN1 antibody. JEM Vol. 208, No. 6 
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